InVivo Therapeutics Announces Appointment of Jeffrey Hatfield to Board of Directors
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Jeffrey Hatfield to its Board of
Directors. Mr. Hatfield most recently served as President, Chief Executive Officer, and Board Member for Vitae Pharmaceuticals and
served in those capacities since joining the company in March 2004. Mr. Hatfield funded the company privately from 2005 to 2014 via
three separate partnering transactions and took Vitae Pharmaceuticals public in 2014. On September 14, 2016, Allergan Plc announced
that it had entered into a definitive agreement to purchase Vitae Pharmaceuticals for approximately $639 million in cash.
Prior to joining Vitae Pharmaceuticals, Mr. Hatfield worked at Bristol-Myers Squibb (BMS) in a variety of executive positions,
including: Senior Vice President of BMS’ Immunology and Virology Divisions, where he was responsible for all aspects of the $1B
annual revenue division; President and General Manager, BMS-Canada; and Vice President, U.S. Managed Health Care. Mr. Hatfield
holds an M.B.A. from The Wharton School of the University of Pennsylvania and a bachelor’s degree in pharmacy from Purdue
University, where he is a Distinguished Alumnus and adjunct professor. He has served on the Board of Ambit Biosciences (AMBI)
before its acquisition by Daiichi-Sankyo, and is currently a member of the Board of Directors of the Biotechnology Industry
Organization (BIO), serving on the Executive Committee of the Emerging Company Section. He is also a member of the advisory
committees for Purdue University’s College of Pharmacy, Drexel University’s LeBow College of Business, and the Chapman-KGI School
of BioPharmacy.
Mark Perrin, InVivo’s CEO and Chairman, said, “The Board of Directors is pleased to welcome Jeff. His invaluable experience in
steering a company to clinical trials, managing successful product launches, business development transactions, and driving
valuation leading to corporate acquisition makes him a great asset to the Board.”
“I’m personally very motivated and excited by the company’s work, as I’ve had direct experience with a family member who
suffered a serious spinal cord injury at an early age,” Hatfield said. “I’m hopeful that Mark and the InVivo team can make a
meaningful difference to the lives of those suffering these kinds of traumatic injury.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on
treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D.,
Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who
now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American
Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational
Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered
in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Investor Relations
bluque@invivotherapeutics.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161102005171/en/